US · CDNA
CareDx, Inc
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- South San Francisco, CA 94080
- Website
- caredx.com
Price · as of 2025-12-31
$21.50
Market cap 964.88M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.56 | +65.4% |
| Intrinsic Value(DCF) | $14.21 | -33.91% |
| Graham-Dodd Method(GD) | $2.93 | -86.39% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | $0.00 | $0.00 | |||
| 2014 | $6.66 | $56.42 | $81.73 | $5.71 | $4.12 |
| 2015 | $5.39 | $144.44 | $1.31 | $0.00 | $0.00 |
| 2016 | $2.25 | $16.48 | $7.02 | $0.00 | $0.00 |
| 2017 | $5.74 | $25.15 | $3.81 | $0.00 | $0.00 |
| 2018 | $34.16 | $52.49 | $423.13 | $0.00 | $0.00 |
| 2019 | $23.43 | $44.15 | $1,345.36 | $0.00 | $0.00 |
| 2020 | $67.54 | $488.72 | $2,479.69 | $3.45 | $0.00 |
| 2021 | $30.78 | $72.10 | $2,719.80 | $5.28 | $0.00 |
| 2022 | $9.53 | $24.38 | $155.51 | $0.19 | $0.00 |
| 2023 | $11.79 | $25.51 | $0.00 | $0.00 | $14.56 |
| 2024 | $18.92 | $130.41 | $4.21 | $11.38 | $26.19 |
| 2025 | $18.75 | $35.56 | $2.39 | $2.93 | $0.00 |
AI valuation
Our deep-learning model estimates CareDx, Inc's (CDNA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.56
- Current price
- $21.50
- AI upside
- +65.4%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$14.21
-33.91% upside
Graham-Dodd
$2.93
-86.39% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| CDNA | CareDx, Inc | $21.50 | 964.88M | +65% | -34% | -86% | — | -46.78 | 3.30 | 2.63 | -1261.39 | — | 4.33 | 66.99% | -5.53% | -5.62% | -6.27% | -14.41% | -4.72% | 0.06 | — | 2.86 | 2.45 | 68.59 | -14301.00% | 1379.00% | 1443.00% | 3.62% | 0.47 | 24.76% | 0.00% | 0.00% | 8.79% | -40.03 | 23.29 | 2.22 | 4.19 |
| CRMD | CorMedix Inc. | $7.13 | 561.77M | — | +1,092,258% | — | — | -35.17 | 7.45 | 14.50 | -30.53 | — | 7.61 | 92.66% | -51.43% | -41.24% | -23.17% | -146.77% | -17.85% | 0.01 | -614.10 | 3.39 | 3.05 | 2.11 | -6703.00% | — | 3096.00% | -8.05% | -1.50 | -358.96% | 0.00% | 0.00% | 0.00% | -25.91 | -11.42 | 13.33 | 7.62 |
| CSTL | Castle Biosciences, Inc. | $29.57 | 863.11M | +72% | -30% | -71% | — | -33.58 | 1.72 | 2.36 | 48.38 | — | 2.19 | 68.66% | -12.44% | -7.02% | -5.21% | -17.64% | -4.35% | 0.08 | -497.79 | 5.26 | 4.99 | -7.04 | -23387.00% | 366.00% | -2248.00% | 3.49% | 0.94 | 14.26% | 0.00% | 0.00% | 0.00% | -12.82 | 19.37 | 1.59 | 4.94 |
| DRIO | DarioHealth Corp. | $11.97 | 80.9M | +162% | -51% | — | — | -22.91 | 13.60 | 36.23 | -19.50 | — | -234.90 | 49.06% | -213.55% | -158.09% | -65.68% | -88.81% | -39.71% | 0.42 | -601.50 | 2.44 | 2.03 | -0.05 | -6839.00% | 3286.00% | 2499.00% | -3.95% | -2.32 | -62.10% | 0.00% | 0.00% | 0.00% | -16.99 | -25.36 | 36.29 | 6.81 |
| EMBC | Embecta Corp. | $10.26 | 607.6M | +264% | -45% | — | -28% | 6.95 | -1.02 | 0.61 | 6.34 | 33.27 | -0.99 | 62.89% | 30.48% | 8.83% | -13.74% | 39.85% | 8.03% | -2.20 | 3.07 | 2.41 | 1.43 | 4.09 | 2090.00% | -380.00% | 81658.00% | 27.50% | 0.73 | 31.54% | 5.28% | 36.70% | 26.66% | 5.67 | 10.24 | 1.73 | 2.05 |
| EVH | Evolent Health, Inc. | $3.25 | 376.91M | +378% | -56% | — | +2,393% | -0.71 | 0.98 | 0.22 | -0.76 | -0.13 | -0.47 | 15.09% | -0.24% | -28.49% | -81.81% | -0.48% | -26.08% | 0.05 | -0.08 | 1.31 | 1.23 | 0.37 | 52593.00% | -2656.00% | -17759.00% | 1.16% | 0.10 | 0.52% | 2.72% | -1.90% | 194.02% | -62.28 | 58.08 | 0.15 | 0.25 |
| FLGT | Fulgent Genetics, Inc. | $15.33 | 473.89M | +1,814% | -46% | +66% | — | -7.09 | 0.39 | 1.35 | -2.21 | -17.85 | 0.43 | 40.56% | -19.10% | -18.75% | -5.49% | -6.54% | -5.07% | 0.00 | -821.75 | 6.48 | 4.95 | 1.08 | 3972.00% | 1383.00% | 54509.00% | -28.42% | -1.20 | -14.97% | 0.00% | 0.00% | 3.19% | -1.65 | -0.82 | 0.31 | 3.63 |
| MRVI | Maravai LifeSciences Hold… | $3.56 | 516.14M | +2,414% | -55% | — | +382% | -2.27 | 2.47 | 2.82 | -4.45 | — | -7.64 | 18.30% | -69.20% | -70.41% | -85.84% | -61.48% | -25.95% | 0.17 | -4.79 | 6.60 | 5.40 | 2.35 | -1429.00% | -2834.00% | 21867.00% | -13.50% | -1.28 | -34.44% | 0.00% | 0.00% | 44.99% | -2.66 | -4.84 | 1.84 | 0.89 |
| MYGN | Myriad Genetics, Inc. | $4.61 | 429.72M | +702% | -57% | — | — | — | 1.27 | 0.57 | -1.33 | — | 2.87 | 69.93% | -16.90% | -44.38% | 0.00% | -22.11% | 0.00% | 0.57 | -11.51 | 2.49 | 1.98 | -0.15 | 18085.00% | -156.00% | -10469.00% | 0.39% | 0.01 | 0.31% | 0.00% | — | 0.00% | -3.79 | 293.13 | 0.64 | -0.54 |
| PSNL | Personalis, Inc. | $9.06 | 804.57M | +263% | — | — | — | -9.95 | 3.10 | — | -8.46 | — | 3.10 | 0.00% | — | — | -35.02% | -152.75% | -26.89% | 0.12 | -429.55 | 6.76 | 6.46 | 1.30 | -3358.00% | -10000.00% | 6994.00% | -9.83% | -1.89 | -137.82% | 0.00% | 0.00% | 5.59% | -6.82 | -7.56 | — | 3.95 |
| VIR | Vir Biotechnology, Inc. | $9.09 | 1.26B | +144% | -52% | — | — | -2.95 | 1.69 | 18.87 | -2.39 | — | 1.75 | 82.92% | -682.68% | -638.87% | -45.73% | -112.47% | -36.47% | 0.24 | — | 5.54 | 5.03 | 0.11 | -1749.00% | -761.00% | -1257.00% | -30.66% | -4.22 | -95.31% | 0.00% | 0.00% | 0.00% | -2.17 | -2.57 | 14.85 | 0.63 |
About CareDx, Inc
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.
- CEO
- John Walter Hanna Jr.
- Employees
- 644
- Beta
- 2.51
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($14.21 ÷ $21.50) − 1 = -33.91% (DCF, example).